A.C. Bay-Jensen
Aggrecanase degradation of type III collagen is associated with clinical knee pain
Bay-Jensen, A.C.; Kjelgaard-Petersen, C.F.; Petersen, K.K.; Arendt-Nielsen, L.; Quasnichka, Helen; Mobasheri, A.; Karsdal, M.A.; Leeming, D.J.
Authors
C.F. Kjelgaard-Petersen
K.K. Petersen
L. Arendt-Nielsen
Helen Quasnichka
A. Mobasheri
M.A. Karsdal
D.J. Leeming
Abstract
There is a lack of biochemical markers for non-invasive and objective assessment of symptomatic osteoarthritis (OA). Aggrecanase activity has been shown to be associated with joint deterioration and symptomatic disease through the degradation of extracellular matrix proteins, such as type III collagen. Our study aimed to identify and develop a novel biomarker by measuring an aggrecanase-mediated type III collagen neoepitope, and correlate levels of this biomarker with OA joint pain. Mass spectrometric analysis of purified type III collagen, degraded by the aggrecanase A Disintigrin and Metalloproteinase with Thrombospondin motif (ADAMTS), revealed a fragment generated by ADAMTS-1, -4 and -8. A monoclonal antibody was raised against the neoepitope of this fragment (COL3-ADAMTS) and a competitive ELISA was developed and tested; using serum samples from a cross-sectional cohort of patients with different degrees of knee OA (n = 261). The COL3/ADAMTS ELISA was technically robust and specific for the ADAMTS-1, -4 and -8 generated neoepitope. COL3/ADAMTS was released form cytokine stimulated synovial cultures, indicating a biologic link between the marker and synovium. In OA patients, serum COL3/ADAMTS was independently associated with pain scores (rho = −0.13–0.17, p < 0.05). This association was associated significantly with the presence of radiographic OA. Together, these data indicate that COL3/ADAMTS could be a marker of early osteoarthritis and the underlining pathology.
Journal Article Type | Article |
---|---|
Acceptance Date | Apr 23, 2018 |
Online Publication Date | Apr 25, 2018 |
Publication Date | Aug 1, 2018 |
Deposit Date | Jun 28, 2023 |
Journal | Clinical Biochemistry |
Print ISSN | 0009-9120 |
Electronic ISSN | 1873-2933 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 58 |
Pages | 37-43 |
DOI | https://doi.org/10.1016/j.clinbiochem.2018.04.022 |
Keywords | Clinical Biochemistry; General Medicine |
Public URL | https://uwe-repository.worktribe.com/output/10339018 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S0009912017307889?via%3Dihub |
Additional Information | This article is maintained by: Elsevier; Article Title: Aggrecanase degradation of type III collagen is associated with clinical knee pain; Journal Title: Clinical Biochemistry; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinbiochem.2018.04.022; Content Type: article; Copyright: © 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. |
You might also like
Chondrogenic differentiation of human chondrocytes cultured in the absence of ascorbic acid
(2018)
Journal Article
Lumican is a potential biomarker for osteoarthritis
(2013)
Presentation / Conference Contribution
Expression of lumican in the synovial fluid of patients with osteoarthritis (OA)
(2011)
Journal Article
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search